Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.

摘要: Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association Urology guidelines panel undertook a systematic review and successfully developed novel BCR risk stratification system (groups with low or high BCR) based on disease prostate-specific antigen characteristics. Patient summary: Following cure cancer, some patients can develop identified via blood test (ie, biochemical recurrence, BCR). However, every man who experiences develops (symptoms evidence progression imaging). We conducted literature classification for predicting which might progress optimize decisions. The EAU-EANM-ESTRO-ESUR-SIOG recommends stratifying experiencing into EAU low-risk high-risk groups. Each patient's profile life expectancy should be considered when discussing benefits toxicities salvage treatments.